Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831 Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Body Mass Index
  • Breast Neoplasms
  • Receptor, ErbB-2

abstract

  • Patients with early stage, HER2-positive breast cancer and normal BMI had a better 5-year DFS compared with overweight and obese women. The current results indicated that adjuvant trastuzumab improves clinical outcome regardless of BMI.

publication date

  • July 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3686994

Digital Object Identifier (DOI)

  • 10.1002/cncr.28051

PubMed ID

  • 23585192

Additional Document Info

start page

  • 2447

end page

  • 54

volume

  • 119

number

  • 13